BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35988455)

  • 1. Multimodal survival prediction in advanced pancreatic cancer using machine learning.
    Keyl J; Kasper S; Wiesweg M; Götze J; Schönrock M; Sinn M; Berger A; Nasca E; Kostbade K; Schumacher B; Markus P; Albers D; Treckmann J; Schmid KW; Schildhaus HU; Siveke JT; Schuler M; Kleesiek J
    ESMO Open; 2022 Oct; 7(5):100555. PubMed ID: 35988455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.
    Yang Z; LaRiviere MJ; Ko J; Till JE; Christensen T; Yee SS; Black TA; Tien K; Lin A; Shen H; Bhagwat N; Herman D; Adallah A; O'Hara MH; Vollmer CM; Katona BW; Stanger BZ; Issadore D; Carpenter EL
    Clin Cancer Res; 2020 Jul; 26(13):3248-3258. PubMed ID: 32299821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection.
    Xie T; Wang X; Li M; Tong T; Yu X; Zhou Z
    Eur Radiol; 2020 May; 30(5):2513-2524. PubMed ID: 32006171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
    Parikh DA; Durbin-Johnson B; Urayama S
    J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT Radiomics-Based Preoperative Survival Prediction in Patients With Pancreatic Ductal Adenocarcinoma.
    Park S; Sham JG; Kawamoto S; Blair AB; Rozich N; Fouladi DF; Shayesteh S; Hruban RH; He J; Wolfgang CL; Yuille AL; Fishman EK; Chu LC
    AJR Am J Roentgenol; 2021 Nov; 217(5):1104-1112. PubMed ID: 34467768
    [No Abstract]   [Full Text] [Related]  

  • 6. Proposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort study.
    Li HJ; Chen YT; Yuan SQ
    Medicine (Baltimore); 2018 Aug; 97(34):e12094. PubMed ID: 30142869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.
    Healy GM; Salinas-Miranda E; Jain R; Dong X; Deniffel D; Borgida A; Hosni A; Ryan DT; Njeze N; McGuire A; Conlon KC; Dodd JD; Ryan ER; Grant RC; Gallinger S; Haider MA
    Eur Radiol; 2022 Apr; 32(4):2492-2505. PubMed ID: 34757450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan.
    Inoue D; Ozaka M; Matsuyama M; Yamada I; Takano K; Saiura A; Ishii H
    Jpn J Clin Oncol; 2015 Jan; 45(1):61-6. PubMed ID: 25341546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
    Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
    Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8
    Chen HY; Wang X; Zhang H; Liu XB; Tan CL
    World J Gastroenterol; 2019 Dec; 25(46):6752-6766. PubMed ID: 31857777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma.
    Porta M; Pumarega J; Amaral AFS; Genkinger JM; Camargo J; Mucci L; Alguacil J; Gasull M; Zhang X; Morales E; Iglesias M; Ogino S; Engel LS;
    Environ Res; 2020 Nov; 190():109781. PubMed ID: 32791343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis.
    Chen YT; Huang ZP; Zhou ZW; He MM
    Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.
    La Torre M; Nigri G; Cavallini M; Mercantini P; Ziparo V; Ramacciato G
    Ann Surg Oncol; 2012 Sep; 19(9):2917-23. PubMed ID: 22488099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    Sci Rep; 2021 Oct; 11(1):20797. PubMed ID: 34675229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma.
    Wu LX; Wang XY; Xu KQ; Lin YL; Zhu WY; Han L; Shao YT; Zhou HY; Jiang H; Hang JJ; Yang XG
    J Cancer; 2019; 10(26):6673-6680. PubMed ID: 31777596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.
    Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA
    J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.